首页 | 本学科首页   官方微博 | 高级检索  
检索        

冰片对黄芪甲苷和三七总皂苷配伍有效成分在脑缺血/再灌注模型大鼠脑组织分布的影响
引用本文:刘晓丹,杨筱倩,唐三,丁煌,黄小平,邓常清.冰片对黄芪甲苷和三七总皂苷配伍有效成分在脑缺血/再灌注模型大鼠脑组织分布的影响[J].中草药,2019,50(7):1649-1656.
作者姓名:刘晓丹  杨筱倩  唐三  丁煌  黄小平  邓常清
作者单位:湖南中医药大学 分子病理实验室, 中西医结合心脑疾病防治湖南省重点实验室, 细胞生物学与分子技术湖南省高校重点实验室, 湖南 长沙 410208,湖南中医药大学 分子病理实验室, 中西医结合心脑疾病防治湖南省重点实验室, 细胞生物学与分子技术湖南省高校重点实验室, 湖南 长沙 410208,湖南中医药大学 分子病理实验室, 中西医结合心脑疾病防治湖南省重点实验室, 细胞生物学与分子技术湖南省高校重点实验室, 湖南 长沙 410208,湖南中医药大学 分子病理实验室, 中西医结合心脑疾病防治湖南省重点实验室, 细胞生物学与分子技术湖南省高校重点实验室, 湖南 长沙 410208,湖南中医药大学 分子病理实验室, 中西医结合心脑疾病防治湖南省重点实验室, 细胞生物学与分子技术湖南省高校重点实验室, 湖南 长沙 410208,湖南中医药大学 分子病理实验室, 中西医结合心脑疾病防治湖南省重点实验室, 细胞生物学与分子技术湖南省高校重点实验室, 湖南 长沙 410208
基金项目:国家自然科学基金资助项目(81573875);湖南省自然科学基金项目(2018JJ3382);湖南省中医药管理局重点项目(201509);湖南省科技厅科技创新平台与人才计划——中医脑病临床研究中心(2017SK4005);"中医药防治心脑血管疾病基础研究"湖南省自然科学创新群体基金
摘    要:目的探讨冰片是否具有促进黄芪甲苷(AST IV)和三七总皂苷(PNS)配伍时主要有效成分透过大脑中动脉栓塞(MCAO)再灌注模型大鼠血脑屏障的作用。方法大鼠随机分为假手术组、模型组、冰片组、AST IV组、PNS组、AST IV+PNS组、冰片+AST IV+PNS组,制备MCAO再灌注大鼠模型,以液相色谱-质谱联用法(LC-MS/MS)测定大鼠患侧与健侧大脑皮层、小脑中AST IV和PNS有效成分(人参皂苷Rg1、Rb1和三七皂苷R1)的含量。结果 AST IV无论是单用还是与PNS、冰片配伍,其口服后主要分布在大脑皮层,尤其是患侧大脑皮层。冰片+AST IV+PNS能使患侧与健侧大脑皮层中AST IV含量显著增加。PNS单用,其有效成分人参皂苷Rg1、Rb1和三七皂苷R1主要分布在患侧小脑。冰片+AST IV+PNS能使患侧大脑皮层中人参皂苷Rb1含量显著增加,使健侧和患侧大脑皮层中人参皂苷Rg1含量增加,使大脑皮层尤其是患侧大脑皮层及小脑中三七皂苷R1含量增加。结论大鼠脑缺血再灌注后,AST IV与PNS的有效成分人参皂苷Rb1、Rg1及三七皂苷R1在大脑皮层和小脑均有一定的分布。AST IV单用时,AST IV主要分布在大脑皮层;PNS单用时,人参皂苷Rb1、Rg1及三七皂苷R1主要分布在小脑。冰片与AST IV、PNS合用后,能促进AST IV及人参皂苷Rb1、Rg1及三七皂苷R1向大脑皮层富集,尤其是向缺血再灌注侧大脑皮层富集;而且能不同程度地促进AST IV,人参皂苷Rb1、Rg1及三七皂苷R1在大脑皮层的吸收,尤其是在患侧大脑皮层的吸收。

关 键 词:脑缺血再灌注  冰片  黄芪甲苷  三七总皂苷  配伍  血脑屏障  药物吸收  人参皂苷Rb1  人参皂苷Rg1  三七皂苷R1
收稿时间:2019/1/8 0:00:00

Study on borneol combined with astragaloside IV and Panax notoginseng saponins promoting bioactive components into brain in cerebral ischemia/reperfusion model of rats
LIU Xiao-dan,YANG Xiao-qian,TANG San,DING Huang,HUANG Xiao-ping and DENG Chang-qing.Study on borneol combined with astragaloside IV and Panax notoginseng saponins promoting bioactive components into brain in cerebral ischemia/reperfusion model of rats[J].Chinese Traditional and Herbal Drugs,2019,50(7):1649-1656.
Authors:LIU Xiao-dan  YANG Xiao-qian  TANG San  DING Huang  HUANG Xiao-ping and DENG Chang-qing
Institution:Molecular Pathology Laboratory, Key Laboratory of Hunan Province for Prevention and Treatment of Integrated Traditional Chinese and Western Medicine on Cardio-Cerebral Diseases, Key Laboratory of Hunan University for Cell Biology and Molecular Techniques, Hunan University of Chinese Medicine, Changsha 410208, China,Molecular Pathology Laboratory, Key Laboratory of Hunan Province for Prevention and Treatment of Integrated Traditional Chinese and Western Medicine on Cardio-Cerebral Diseases, Key Laboratory of Hunan University for Cell Biology and Molecular Techniques, Hunan University of Chinese Medicine, Changsha 410208, China,Molecular Pathology Laboratory, Key Laboratory of Hunan Province for Prevention and Treatment of Integrated Traditional Chinese and Western Medicine on Cardio-Cerebral Diseases, Key Laboratory of Hunan University for Cell Biology and Molecular Techniques, Hunan University of Chinese Medicine, Changsha 410208, China,Molecular Pathology Laboratory, Key Laboratory of Hunan Province for Prevention and Treatment of Integrated Traditional Chinese and Western Medicine on Cardio-Cerebral Diseases, Key Laboratory of Hunan University for Cell Biology and Molecular Techniques, Hunan University of Chinese Medicine, Changsha 410208, China,Molecular Pathology Laboratory, Key Laboratory of Hunan Province for Prevention and Treatment of Integrated Traditional Chinese and Western Medicine on Cardio-Cerebral Diseases, Key Laboratory of Hunan University for Cell Biology and Molecular Techniques, Hunan University of Chinese Medicine, Changsha 410208, China and Molecular Pathology Laboratory, Key Laboratory of Hunan Province for Prevention and Treatment of Integrated Traditional Chinese and Western Medicine on Cardio-Cerebral Diseases, Key Laboratory of Hunan University for Cell Biology and Molecular Techniques, Hunan University of Chinese Medicine, Changsha 410208, China
Abstract:Objective To investigate whether borneol can promote the bioactive components of the combination of astragaloside IV (AST IV) and Panax notoginseng saponins (PNS) into the blood-brain barrier of rats with middle cerebral artery occlusion (MCAO)/reperfusion. Methods Using the model of MCAO/reperfusion, rats were randomly divided into sham-operation group, model group, borneol group, AST IV group, PNS group, AST IV + PNS group and borneol + AST IV + PNS group, and the content of AST IV and the bioactive components of PNS (ginsenoside Rg1, ginsenoside Rb1, and notoginsenoside R1) in the cerebral cortex and the cerebellum of the affected side and the healthy side were determined by liquid chromatography-mass spectrometry (LC-MS/MS). Results AST IV, whether used alone or combined with PNS and borneol, was mainly distributed in the cerebral cortex after oral administration, especially in the affected cerebral cortex. Borneol combined with AST IV and PNS significantly increased the content of AST IV in the affected and the healthy cerebral cortex. The bioactive components of PNS such as ginsenoside Rg1, ginsenoside Rb1, and notoginsenoside R1 was mainly distributed in the affected side of the cerebellum when PNS was used alone. Borneol combined with AST IV + PNS significantly increased the content of ginsenoside Rb1 in the cerebral cortex, especially in the affected cortex, increased the content of Rg1 in the healthy and the affected cortex, and increased the content of notoginsenoside R1 in the cerebral cortex, especially in the affected cortex, as well as in the cerebellum. Conclusion AST IV and the bioactive components of PNS such as ginsenoside Rg1, ginsenoside Rb1, and notoginsenoside R1 have a certain distribution in the cerebral cortex and the cerebellum after cerebral ischemia-reperfusion in rats. AST IV was mainly distributed in the cerebral cortex when it was used alone, ginsenoside Rg1, ginsenoside Rb1, and notoginsenoside R1 were mainly distributed in the cerebellum when PNS was used alone. The combination of borneol combined with AST IV and PNS can promote the gather of AST IV, ginsenoside Rg1, ginsenoside Rb1, and notoginsenoside R1 to the cerebral cortex, especially to the cortex of the ischemia-reperfusion side; Moreover, it can promote the absorption of AST IV, ginsenoside Rg1, ginsenoside Rb1, and notoginsenoside R1 in the cerebral cortex to varying degrees, especially in the affected cortex.
Keywords:cerebral ischemia-reperfusion  borneol  astragaloside IV  Panax notoginseng saponins  combination  blood-brain barrier  drug absorption  ginsenoside Rb1  ginsenoside Rg1  notoginsenoside R1
本文献已被 CNKI 等数据库收录!
点击此处可从《中草药》浏览原始摘要信息
点击此处可从《中草药》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号